Loading...

The Global Health Investment Corporation (GHIC) is a non-profit established to provide long-term funding for global health research and development through financing vehicles such as the Global Health Investment Fund. The GHIC is the Managing Member of the Fund and is a US-registered 501(c)(4). It is governed by an independent board of directors who bring diverse expertise from backgrounds in the pharmaceutical industry, venture capital, investment banking, philanthropy and international development.

Board Members

Labeeb Abboud
Labeeb AbboudChairman and CEO, GHIF
Bill Greene, Director
Bill Greene, DirectorPresident and CEO of Iconic Therapeutics, Inc.
Kai Gesing, Director
Kai Gesing, DirectorSenior Health and Population Expert at KfW Development Bank
George Wellde, Director
George Wellde, DirectorFormer Vice Chairman of the Securities Division at Goldman, Sachs & Co.

Emeritus Board Members

Wolfgang Bichmann, Director 2013-2020
Wolfgang Bichmann, Director 2013-2020Former Head of Sector and Policy Division - Health, Education and Social Protection at KfW
Andrin Oswald, Director 2013-2020
Andrin Oswald, Director 2013-2020CEO of Centogene
Lynn Eisenhart, Director 2020-2021
Lynn Eisenhart, Director 2020-2021Deputy Director, Gates Foundation Strategic Investment Fund

Team

Curt LaBelle, MD, President of Global Health Investment Corporation
Curt LaBelle, MD, President of Global Health Investment CorporationManaging Partner, Global Health Investment Fund
Evelyn Yanatos
Evelyn YanatosAssistant Treasurer and Secretary
Zina Affas Besse
Zina Affas BesseAdvisor

Investment Oversight that Considers Financial Returns and Social Impact

GHIF investments are subject to the approval of an independent Investment Committee and a Charitability Oversight Committee. In addition, the Fund leverages the expertise of its investor base via an Investor Advisory Committee and a Scientific Advisory Committee. Collectively, these committees constitute a robust investment review and governance structure for the Fund.

Investment Committee

The GHIF Investment Committee is charged with ensuring prospective and portfolio investments meet the Fund’s financial return objectives.

Investor Advisory Committee

The Investor Advisory Committee represents the interests of the Fund’s limited partners and advises on major strategic or operational questions.

Scientific Advisory Committee

The Scientific Advisory Committee is an incredible resource to the GHIF, providing access to the foremost research and development experts for advice on the technical merits of GHIF investment opportunities.

Charitability Oversight Committee (COC)

The COC ensures that the Fund’s activities are in compliance with Program-Related Investment requirements, as defined by the US tax code. The COC also advises on social impact measurement and reporting.

How GHIF Works

GHIF Oversight Committees and Disclosures

  • Karlee Silver, Co-Chief Executive Officer, Grand Challenges Canada
  • Imraan Mohammed, Director, Programme Related Investments (PRI), Children’s Investment Fund Foundation
  • Jeffrey Haines, Head, Deal Finance and M&A, Worldwide Business Development, GlaxoSmithKline
  • Chris McCahan, Chief Investment Officer – Consumer & Social Services, International Finance Corporation
  • David Glatt, Executive Director and New Products Leader – Infectious Diseases, Merck
  • Jonathan Dean, Portfolio Manager, AXA Investment Managers
  • Jenny Sia, Senior Director of Operations – Corporate Responsibility, Pfizer

The Charitability Oversight Committee reviews compliance with charitable restrictions and Program-Related Investment (PRI) requirements, in addition to monitoring the social impact of GHIF investments.

  • Janice Culpepper, Senior Program Officer, Bill & Melinda Gates Foundation
  • Natalie Revelle, Strategic Investment Fund, Bill & Melinda Gates Foundation
  • Alex Siegel, Strategic Investment Fund, Bill & Melinda Gates Foundation
  • Jocelyn Mackie, Co-Chief Executive Officer, Grand Challenges Canada
  • Andrea Gaius-Obaseki, Project Manager – Health, Education, Social Protection (LAB2), KfW Development Bank – Germany
  • Lena Rupp, Senior Program Manager – Loans and Guarantees Unit, Department for Partnerships and Innovation, Swedish International Development Cooperation Agency

The Scientific Advisory Committee provides scientific and technical guidance to the Global Health Investment Fund, with representation from the Bill & Melinda Gates Foundation and some of the senior-most executives from the Fund’s strategic investors.

  • Trevor Mundel, President of Global Health, Bill & Melinda Gates Foundation
  • Bill Gruber, Senior Vice President of Vaccine Clinical Research and Development, Pfizer
  • [To Be Named], GlaxoSmithKline
  • Roger Perlmutter, Executive Vice President and President of Merck Research Laboratories, Merck

As a 501(c)(4) non-profit organization under the US tax code, the Global Health Investment Corporation publicly discloses its annual Form 990 as filed with the Internal Revenue Service. Recent annual filings can be downloaded for the years listed below.